Mounjaro (Tirzepatide) Blood Test Monitoring

Mounjaro (tirzepatide) has rapidly become one of the most talked-about weight loss drugs in the UK. Approved by NICE in late 2023 for weight management in adults with a BMI of 30 or above (or 27 with weight-related comorbidities), it represents a new class of medication: a dual GLP-1 and GIP receptor agonist. It works through a different mechanism than semaglutide (Ozempic/Wegovy), and the clinical data suggests it produces even greater weight loss — up to 22.5% of body weight in the SURMOUNT-1 trial.

But more potent weight loss comes with its own set of monitoring requirements. If you're taking Mounjaro — whether prescribed by the NHS or through a private clinic — regular blood testing is not a nice-to-have. It's a clinical necessity.

Important: This article is for information only. It is not medical advice. Always consult your prescribing doctor about monitoring requirements for any medication.

How Mounjaro Differs from Semaglutide

While semaglutide acts on GLP-1 receptors alone, tirzepatide targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism produces several differences that are relevant to blood monitoring:

• Greater weight loss — the SURMOUNT trials showed 22.5% average weight loss at the highest dose, compared to 15% for semaglutide
• Stronger effects on liver enzymes — tirzepatide has shown larger reductions in ALT in clinical trials, suggesting a bigger impact on liver fat
• Greater improvement in lipid profiles — tirzepatide reduces triglycerides and LDL cholesterol more than semaglutide, while raising HDL more substantially
• More pronounced insulin sensitisation — the GIP component adds an additional pathway for improving glucose metabolism

These differences mean that while the core monitoring requirements overlap with semaglutide, there are areas where tirzepatide users should pay extra attention — particularly lipids and liver function.

Liver Function Monitoring

Tirzepatide appears to be particularly effective at reducing liver fat. In the SURPASS trials (for type 2 diabetes), ALT levels dropped significantly — a positive sign for people with non-alcoholic fatty liver disease. However, this same potency means the liver is working hard to process mobilised fat stores, and in some individuals, liver enzymes can spike before they improve.

The full liver panel to monitor includes:

• ALT — the most specific liver marker; expect it to fluctuate, particularly in the first 3 months
• AST — complementary liver enzyme; helps distinguish liver injury from muscle breakdown
• GGT — critical for detecting gallbladder issues, which are a known risk of rapid weight loss on GLP-1/GIP drugs
• ALP — rises with bile duct obstruction; gallstone-related complications
• Bilirubin — the final checkpoint for liver processing capacity

Gallstone risk deserves special mention. Rapid weight loss of any kind increases gallstone formation because the liver secretes more cholesterol into bile as fat stores are mobilised. With tirzepatide producing faster weight loss than semaglutide, the gallstone risk may be proportionally higher. GGT and ALP are your early warning markers.

Kidney Function Monitoring

The same dehydration concerns that apply to semaglutide are relevant here. Tirzepatide suppresses appetite and thirst, and gastrointestinal side effects (nausea, vomiting, diarrhoea) can compound fluid loss. The kidneys bear the brunt of chronic dehydration.

Monitor these markers:

• Creatinine — rising levels indicate the kidneys are under stress
• eGFR — the gold standard for assessing kidney function; anything below 90 warrants attention, below 60 is concerning
• Urea — rises disproportionately with dehydration, making it a useful early signal

A practical tip: many Mounjaro users report that they forget to drink water because their appetite suppression extends to thirst. If your urea is rising while creatinine stays stable, that's a dehydration signal — not kidney damage — but it still needs addressing.

Lipid Panel: Where Tirzepatide Stands Out

One of the most striking findings from tirzepatide clinical trials is its effect on blood lipids. In the SURPASS-2 trial comparing tirzepatide to semaglutide in type 2 diabetes, tirzepatide produced significantly greater reductions in triglycerides and larger increases in HDL cholesterol.

A full lipid panel while on Mounjaro should include:

• Total cholesterol — expect this to decrease
• LDL cholesterol — should drop, though the extent varies
• HDL cholesterol — should increase; tirzepatide has shown up to 8% improvement
• Triglycerides — often the most dramatic improvement; reductions of 20–30% are common
• Non-HDL cholesterol — a better predictor of cardiovascular risk than LDL alone

Tracking lipids before and during treatment quantifies the cardiovascular benefit you're getting — useful information for both you and your prescribing clinician.

Thyroid Function

Like semaglutide, tirzepatide carries a precautionary note regarding thyroid C-cell tumours observed in animal studies. No causal link has been confirmed in humans, but the precaution applies to the entire GLP-1 class. TSH and Free T4 should be checked at baseline and periodically during treatment.

Anyone with a history of medullary thyroid carcinoma or MEN 2 syndrome should not take tirzepatide.

HbA1c and Blood Glucose

Whether you're taking Mounjaro for diabetes or weight management, HbA1c tracking shows the metabolic impact of treatment. Tirzepatide is exceptionally effective at lowering HbA1c — in the SURPASS-1 trial, the highest dose achieved an average HbA1c of 34 mmol/mol (5.3%), which is well within the non-diabetic range.

For people without diabetes using Mounjaro for weight loss, monitor HbA1c anyway. It confirms that insulin sensitivity is improving and provides evidence of metabolic benefit beyond the number on the scales.

Nutritional Markers

Greater weight loss means greater nutritional risk. If tirzepatide users are losing more weight more quickly than semaglutide users, they're also depleting nutritional stores faster. The key markers to watch:

• Ferritin — iron stores decline when food intake drops. Below 30 µg/L causes fatigue and weakness.
• Vitamin D — already deficient in most UK adults; calorie restriction worsens it. Target above 75 nmol/L.
• Active B12 — reduced food intake means less dietary B12. Particularly concerning if you're also on metformin.
• Folate — needed for cell division and energy. Drops quickly with reduced vegetable intake.
• Full blood count — detects anaemia, which can develop silently alongside nutritional depletion.

Muscle loss is another concern with rapid weight loss. While blood tests can't directly measure muscle mass, persistently low protein intake reflected in declining albumin levels, combined with elevated CK (creatine kinase), may suggest you're losing muscle alongside fat. Resistance exercise and adequate protein intake are essential countermeasures.

Recommended Testing Schedule

• Before starting Mounjaro: full baseline covering liver, kidney, thyroid, lipids, HbA1c, nutritional markers, and FBC
• 3 months after starting (or after each dose increase): repeat all markers. This is when changes are most likely to appear.
• Every 6 months: ongoing monitoring for as long as you're on treatment
• If you experience symptoms: severe abdominal pain, yellowing skin, persistent vomiting, or unusual fatigue — test immediately

Which Blood Test to Order

The Core Health 45 test (£120) covers the essential monitoring panel: liver function, kidney function, thyroid, HbA1c, vitamin D, B12, ferritin, iron, folate, and FBC. This is the right choice for routine 3- or 6-monthly monitoring.

For liver and kidney monitoring specifically — particularly if you just want to check these between full panels — the Liver & Kidney Function test (£81) is a cost-effective option.

Because tirzepatide has such a pronounced effect on lipids, adding the Cardiovascular Health test (£83) to your monitoring is worthwhile. It includes a full lipid panel alongside HbA1c, giving you a clear picture of your cardiovascular risk profile and how it's improving with treatment.

Mounjaro is a powerful drug that deserves proper monitoring. Don't assume your private prescriber is running all the tests you need. Take control of your own blood work, order a test, and get your results in 2–3 working days. Your body is changing rapidly — make sure you can see exactly how.